Novartis gets EC nod for Adakveo to prevent pain crises in sickle cell disease patients

This article was originally published here

Adakveo can be provided as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate, said Novartis. Adakveo attaches to

The post Novartis gets EC nod for Adakveo to prevent pain crises in sickle cell disease patients appeared first on Pharmaceutical Business review.